However, younger patients with MCD and N1 DLBCL subtypes had a superior 3-year EFS of 100% with ibrutinib plus R-CHOP, as compared to 42.9% and 50%, respectively, with R-CHOP alone [144]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.